Form 4: ProMIS Neurosciences Chief Scientific Officer Acquires 200,000 Stock Options

ProMIS Neurosciences' Chief Scientific Officer, Neil Cashman, was granted 200,000 stock options on November 18, 2024, which vest over a 48-month period.

Summary

• Neil Cashman, the Chief Scientific Officer of ProMIS Neurosciences Inc., was granted 200,000 stock options on November 18, 2024.
• These options have an exercise price of $1 per share.
• The options vest over a 48-month period, with 25% vesting on November 18, 2025, and the remaining 75% vesting ratably over the following 36 months.
• The options expire on November 18, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with the long-term success of the company.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry.
• The vesting schedule of 25% after one year and the remainder over the following three years is a typical vesting schedule for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder value if the executive's performance leads to company growth.

Key Dates

Keywords

stock options, insider trading, executive compensation, vesting, ProMIS Neurosciences, Neil Cashman